Innovation in Bioanalytical Strategies and in vitro Drug–drug Interaction Study Approaches in Drug Discovery

References

• Takebe T , ImaiR, OnoS. The current status of drug discovery and development as originated in United States academia: the influence of industrial and academic collaboration on drug discovery and development. Clin. Transl. Sci.11(6), 597–606 (2018).
   PubMed Web of Science ®Google Scholar
• Hennessy S , FlockhartDA. The need for translational research on drug–drug interactions. Clin. Pharmacol. Ther.91(5), 771–773 (2012).
   PubMed Web of Science ®Google Scholar
• Hughes JP , ReesS, KalindjianSB, PhilpottKL. Principles of early drug discovery. Br. J. Pharmacol.162(6), 1239–1249 (2011).
   PubMed Web of Science ®Google Scholar
• Lu C , DiL. In vitro and in vivo methods to assess pharmacokinetic drug– drug interactions in drug discovery and development. Biopharm. Drug Dispos.41(1–2), 3–31 (2020).
   PubMed Web of Science ®Google Scholar
• Hebenstreit D , PichlerR, HeideggerI. Drug–drug interactions in prostate cancer treatment. Clin. Genitourin Cancer18(2), e71–e82 (2020).
   PubMed Web of Science ®Google Scholar
• Gujjarlamudi HB . Polytherapy and drug interactions in elderly. J. Midlife Health7(3), 105–107 (2016).
   PubMedGoogle Scholar
• Fahmi OA , RippSL. Evaluation of models for predicting drug–drug interactions due to induction. Expert Opin. Drug Metab. Toxicol.6(11), 1399–1416 (2010).
   PubMed Web of Science ®Google Scholar
• Palleria C , DiPaolo A, GiofrèCet al. Pharmacokinetic drug–drug interaction and their implication in clinical management. J. Res. Med. Sci.18(7), 601 (2013).
   PubMed Web of Science ®Google Scholar
• Hakkola J , HukkanenJ, TurpeinenM, PelkonenO. Inhibition and induction of CYP enzymes in humans: an update. Arch. Toxicol.94, 3671–3722 (2020).
   PubMed Web of Science ®Google Scholar
• Tornio A , FilppulaAM, NiemiM, BackmanJT. Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin. Pharmacol. Ther.105(6), 1345–1361 (2019).
   PubMed Web of Science ®Google Scholar
• Yu H , TweedieD. A perspective on the contribution of metabolites to drug–drug interaction potential: the need to consider both circulating levels and inhibition potency. Drug Metab. Dispos.41(3), 536–540 (2013).
   PubMed Web of Science ®Google Scholar
• USFDA . Guidances (Drugs) (2012). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
   Google Scholar
• European Medicine Agency . Guideline on the Investigation of Drug Interactions. 44, 1–59 (2015).
   Google Scholar
• Stampella A , RizzitelliG, DonatiFet al. Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug–drug interaction and metabolism studies. Toxicol. In Vitro30(1), 331–340 (2015).
   PubMed Web of Science ®Google Scholar
• Shinha K , NiheiW, OnoT, NakazatoR, KimuraH. A pharmacokinetic–pharmacodynamic model based on multi-organ-on-a-chip for drug–drug interaction studies. Biomicrofluidics14(4), 044108 (2020).
   PubMed Web of Science ®Google Scholar
• Shibata Y , TakahashiH, ChibaM, IshiiY. A novel approach to the prediction of drug–drug interactions in humans based on the serum incubation method. Drug Metab. Pharmacokinet.23(5), 328–339 (2008).
   PubMed Web of Science ®Google Scholar
• Horspool AM , WangT, ScaringellaYS, TaubME, ChanTS. Human liver microsomes immobilized on magnetizable beads: a novel approach to study in vitro drug metabolism. Drug Metab. Dispos.48(8), 645–654 (2020).
   PubMed Web of Science ®Google Scholar
• Mattei G , GiustiS, AhluwaliaA. Design criteria for generating physiologically relevant in vitro models in bioreactors. Processes2(3), 548–569 (2014).
   Google Scholar
• Rodriguez-Garcia A , Oliva-RamirezJ, Bautista-FloresC, HosseiniS. 3D in vitro human organ mimicry devices for drug discovery, development, and assessment. Adv. Polym. Tech.2, 2020 (2020).
   Google Scholar
• Chung TDY , TerryDB, SmithLH. In vitro and in vivo assessment of ADME and PK properties during lead selection and lead optimization–guidelines, benchmarks and rules of thumb. Assay Guidance Manual1, 1261–1280 (2015).
   Google Scholar
• Andrade EL , BentoAF, CavalliJet al. Non-clinical studies required for new drug development–Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies. Braz. J. Med. Biol. Res.49(11), (2016).
   Web of Science ®Google Scholar
• Jia L , LiuX. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab.8(8), 822–829 (2007).
   PubMed Web of Science ®Google Scholar
• Campbell JE , CohallD. Pharmacodynamics–a pharmacognosy perspective. Pharmacognosy. Elsevier, 513–525 (2017).
   Google Scholar
• Kremers P . In vitro tests for predicting drug–drug interactions: the need for validated procedures. Pharmacol. Toxicol.91(5), 209–217 (2002).
   PubMedGoogle Scholar
• Ogu CC , MaxaJL. Drug interactions due to cytochrome P450. Baylor Univ. Med. Cent. Proc.13(4), 421–423 (2000).
   PubMedGoogle Scholar
• Alsanosi SMM , SkiffingtonC, PadmanabhanS. Pharmacokinetic pharmacogenomics. In: Handbook of Pharmacogenomics and Stratified Medicine.Elsevier Inc, 341–364 (2014).
   Google Scholar
• Shetty V , ChowtaMN, ChowtaKN, ShenoyA, KamathA, KamathP. Evaluation of potential drug–drug interactions with medications prescribed to geriatric patients in a tertiary care hospital. J. Aging Res.2018, 1–6 (2018).
   Google Scholar
• Tripathi KD . General Pharmacological Principles. In: Essentials of Medical Pharmacology (7th Edition). Jaypee, 928–934 (2013).
   Google Scholar
• Zhou S , ChanSY, GohBCet al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet.44(3), 279–304 (2005).
   PubMed Web of Science ®Google Scholar
• Cascorbi I . Drug interactions-principles, examples and clinical consequences. Dtsch Arztebl Int.109(33–34), 546–556 (2012).
   PubMed Web of Science ®Google Scholar
• Brodie MJ , MintzerS, PackAM, GidalBE, VechtCJ, SchmidtD. Enzyme induction with antiepileptic drugs: cause for concern?Epilepsia54(1), 11–27 (2013).
   PubMed Web of Science ®Google Scholar
• Maddi S , GoudT, SrivastavaP. Cytochrome P450 enzymes, drug transporters and their role in pharmacokinetic drug–drug interactions of xenobiotics: a comprehensive review. Open J. Chem.3, 001–011 (2017).
   Google Scholar
• European Pharmaceutical Review . Drug–Drug Interactions: Tools for Drug Transporter Protein Studies (2009). https://www.europeanpharmaceuticalreview.com/article/782/drug-drug-interactions-tools-for-drug-transporter-protein-studies/
   Google Scholar
• Zhang L , StrongJM, QiuW, LeskoLJ, HuangSM. Scientific perspectives on drug transporters and their role in drug interaction. Mol. Pharm.3(1), 62–69 (2006).
   PubMed Web of Science ®Google Scholar
• Joshi A , KieselBF, ChaphekarNet al. In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Cancer Chemother. Pharmacol.86(5), 633–640 (2020).
   PubMed Web of Science ®Google Scholar
• Wu Q , JiangH, WangSet al. Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats. Thorac. Cancer11(10), 2775–2781 (2020).
   PubMed Web of Science ®Google Scholar
• Chen N , CuiD, WangQ, WenZ, FinkelmanRD, WeltyD. In vitro drug–drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes. Xenobiotica48(6), 637–646 (2018).
   PubMed Web of Science ®Google Scholar
• Mukoyoshi M , NishimuraS, HoshideSet al. In vitro drug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica38(5), 496–510 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Y , WangC, WangSet al. Cytochrome P450-based drug–drug interactions of vonoprazan in vitro and in vivo. Front. Pharmacol.11, 1–9 (2020).
   PubMed Web of Science ®Google Scholar
• Seo S-W , ParkJW, HanD-Get al. In vitro and in vivo assessment of metabolic drug interaction potential of dutasteride with ketoconazole. Pharmaceutics11(12), 673 (2019).
   PubMed Web of Science ®Google Scholar
• Shimakura J , TaniN, MizunoY, KomuroS, KanamaruH. In vitro drug–drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur. J. Drug Metab. Pharmacokinet.28(I), 67–72 (2003).
   PubMedGoogle Scholar
• Rautio J , HumphreysJE, WebsterLOet al. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos.34(5), 786–792 (2006).
   PubMed Web of Science ®Google Scholar
• Kosloski MP , BowDA, KikuchiRet al. Translation of in vitro transport inhibition studies to clinical drug–drug interactions for glecaprevir and pibrentasvir s. J. Pharmacol. Exp. Ther.370(2), 278–287 (2019).
   PubMed Web of Science ®Google Scholar
• Shitara Y , ItohT, SatoH, LiAP, SugiyamaY. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug–drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther.304(2), 610–616 (2003).
   PubMed Web of Science ®Google Scholar
• Parmentier Y , BossantM-J, BertrandM, WaltherB. In vitro studies of drug metabolism. Compr. Med. Chem. II5, 231–257 (2006).
   Google Scholar
• Ackley DC , RockichKT, BakerTR. Metabolic stability assessed by liver microsomes and hepatocytes. Optim. Drug Discov.1, 151–162 (2004).
   Google Scholar
• Richardson SJ , BaiA, KulkarniAA, MoghaddamMF. Efficiency in drug discovery: liver S9 fraction assay as a screen for metabolic stability. Drug Metab. Lett.10(2), 83–90 (2016).
   PubMedGoogle Scholar
• Pilchova I , KlacanovaK, TatarkovaZ, KaplanP, RacayP. The involvement of Mg 2 + in regulation of cellular and mitochondrial functions. Oxid. Med. Cell Longev.2017, 1–8 (2017).
   Web of Science ®Google Scholar
• Houston JB , GaletinA. In vitro techniques to study drug–drug interactions of drug metabolism: cytochrome P450. In: Enzyme- and Transporter- Based Drug–Drug Interactions. Springer, 169–215 (2010).
   Google Scholar
• Di Marco A , MarcucciI, VerdirameMet al. Development and validation of a high-throughput radiometric CYP3A4/5 inhibition assay using tritiated testosterone. Drug Metab. Dispos.33(3), 349–358 (2005).
   PubMed Web of Science ®Google Scholar
• Fowler S , ZhangH. In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug–drug interactions. AAPS J.10(2), 410–424 (2008).
   PubMed Web of Science ®Google Scholar
• Trubetskoy OV , GibsonJR, MarksBD. Highly miniaturized formats for in vitro drug metabolism assays using Vivid® fluorescent substrates and recombinant human cytochrome P450 enzymes. J. Biomol. Screen.10(1), 56–66 (2005).
   PubMedGoogle Scholar
• Crespi CL , MillerVP, PenmanBW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem.248(1), 188–190 (1997).
   PubMed Web of Science ®Google Scholar
• Hossain MJ , SultanMZ, RashidMA, KuddusMR. Does rabeprazole sodium alleviate the anti-diabetic activity of linagliptin? drug–drug interaction analysis by in vitro and in vivo methods. Drug Res.70(11), 519–527 (2020).
   Web of Science ®Google Scholar
• Yong YF , TanSC, LiewMWO, YaacobNS. Liquid chromatography-tandem mass spectrometry (LC–MS/MS) method development for screening of potential tamoxifen-drug/herb interaction via in vitro cytochrome P450 inhibition assay. J. Chromatogr. B1148, 122148 (2020).
   PubMed Web of Science ®Google Scholar
• Bjornsson TD , CallaghanJT, EinolfHJet al. The conduct of in vitro and in vivo drug–drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol.43(5), 443–469 (2003).
   PubMed Web of Science ®Google Scholar
• Yu C . Metabolism and in vitro drug–drug interaction assessment of viloxazine. Xenobiotica50(11), 1285–1300 (2020).
   PubMed Web of Science ®Google Scholar
• Peng Y , WuH, ZhangXet al. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug–drug interaction evaluation. Xenobiotica45(11), 961–977 (2015).
   PubMed Web of Science ®Google Scholar
• Scherf-Clavel O , KinzigM, StoffelMS, FuhrU, SörgelF. Quantification of adefovir and pitavastatin in human plasma and urine by LC–MS/MS: a useful tool for drug–drug interaction studies. J. Chromatogr. B.1125, 121718 (2019).
   PubMed Web of Science ®Google Scholar
• Liu J , ZhongX, JiangYet al. Systematic identification metabolites of hemerocallis citrina Borani by high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry combined with a screening method. J. Pharm. Biomed. Anal.186, 113314 (2020).
   PubMed Web of Science ®Google Scholar
• Elgawish MS , SoltanMK, SebaiyMM. Molecular modeling, spectrofluorimetric, and tandem mass spectrometric analysis reveal a competitive binding of amlodipine and rosuvastatin to plasma albumin: insight into drug–drug interaction. Microchem. J.149, 104014 (2019).
   Web of Science ®Google Scholar
• Balhara A , LadumorM, SinghDKet al. In vitro evaluation of reactive nature of E- and Z-guggulsterones and their metabolites in human liver microsomes using UHPLC-Orbitrap mass spectrometer. J. Pharm. Biomed. Anal.186, 113275 (2020).
   PubMed Web of Science ®Google Scholar
• Di L . Reaction phenotyping to assess victim drug–drug interaction risks. Expert Opin. Drug Discov.12(11), 1105–1115 (2017).
   PubMed Web of Science ®Google Scholar
• Gabriel L , TodM, GoutelleS. Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin. Pharmacokinet.55(8), 977–990 (2016).
   PubMed Web of Science ®Google Scholar
• Turpeinen M , RaunioH, PelkonenO. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab.7(7), 705–714 (2006).
   PubMed Web of Science ®Google Scholar
• Daily EB , AquilanteCL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics10(9), 1489–1510 (2009).
   PubMed Web of Science ®Google Scholar
• Booven DV , MarshS, McLoedH. Cytochrome P450 2C9-CYP2C9. NIH public access. Bone20(4), 277–281 (2010).
   Google Scholar
• Joanna KT , RebeccaNC, MichelleDWet al. Cytochrome P450 3A4 and CYP3A5-catalyzed bioactivation of lapatinib. Drug Metab Dispos.44(10), 1584–1597 (2014).
   Web of Science ®Google Scholar
• Rendic S . Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev.34(1–2), 83–448 (2002).
   PubMed Web of Science ®Google Scholar
• Dalvie D , DiL. Aldehyde oxidase and its role as a drug metabolizing enzyme. Pharmacol. Ther.201, 137–180 (2019).
   PubMed Web of Science ®Google Scholar
• Shen Y , ShiZ, YanB. Carboxylesterases: pharmacological inhibition regulated expression and transcriptional involvement of nuclear receptors and other transcription factors. Nucl. Recept. Res.6, 1–15 (2019).
   Google Scholar
• Polasek TM , ElliotDJ, SomogyiAA, GillamEMJ, LewisBC, MinersJO. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br. J. Clin. Pharmacol.61(5), 570–584 (2006).
   PubMed Web of Science ®Google Scholar
• Ryu SD , YiHG, ChaYNet al. Flavin-containing monooxygenase activity can be inhibited by nitric oxide-mediated S-nitrosylation. Life Sci.75(21), 2559–2572 (2004).
   PubMed Web of Science ®Google Scholar
• Celius T , PansoyA, MatthewsJet al. Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver. Toxicol. Appl. Pharmacol.247(1), 60–69 (2010).
   PubMed Web of Science ®Google Scholar
• Mohos V , Fliszár-NyúlE, PoórM. Inhibition of xanthine oxidase-catalyzed xanthine and 6-mercaptopurine oxidation by flavonoid aglycones and some of their conjugates. Int. J. Mol. Sci.21(9), 3256 (2020).
   PubMed Web of Science ®Google Scholar
• Ercan S , KencebayC, BasaranlarG, DerinN, AslanM. Induction of xanthine oxidase activity, endoplasmic reticulum stress and caspase activation by sodium metabisulfite in rat liver and their attenuation by Ghrelin. Food Chem. Toxicol.76, 27–32 (2015).
   PubMed Web of Science ®Google Scholar
• Koppaka V , ThompsonDC, ChenYet al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Rev.64(3), 520–539 (2012).
   PubMed Web of Science ®Google Scholar
• Lv X , XiaY, FinelM, WuJ, GeG, YangL. Recent progress and challenges in screening and characterization of UGT1A1 inhibitors. Acta Pharm. Sin. B9(2), 258–278 (2019).
   PubMed Web of Science ®Google Scholar
• Marques SC , IkediobiON. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum. Genom.4(4), 238 (2010).
   PubMedGoogle Scholar
• You BH , GongEC, ChoiYH. Inhibitory effect of sauchinone on UDP-glucuronosyltransferase (UGT) 2B7 activity. Molecules23(2), 366 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Z , WongT, HashizumeTet al. Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability. Endocrinology155(6), 2052–2063 (2014).
   PubMed Web of Science ®Google Scholar
• Jiang L , LiangSC, WangCet al. Identifying and applying a highly selective probe to simultaneously determine the O-glucuronidation activity of human UGT1A3 and UGT1A4. Sci. Rep.5(1), 1–7 (2015).
   Google Scholar
• Krishnaswamy S , HaoQ, Von MoltkeLL, GreenblattDJ, CourtMH. Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. Drug Metab. Dispos.32(8), 862–869 (2004).
   PubMed Web of Science ®Google Scholar
• Hu DG , MackenziePI, LuL, MeechR, McKinnonRA. Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 Cells. Drug Metab. Dispos.43(5), 660–668 (2015).
   PubMed Web of Science ®Google Scholar
• Barre L , Fournel-GigleuxS, FinelM, NetterP, MagdalouJ, OuzzineM. Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7: identification of a critical aromatic amino acid residue at position 33. FEBS J.274(5), 1256–1264 (2007).
   PubMed Web of Science ®Google Scholar
• Sten T , FinelM, AskB, RaneA, EkströmL. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation. Steroids74(12), 971–977 (2009).
   PubMed Web of Science ®Google Scholar
• De Leon J . Glucuronidation enzymes, genes and psychiatry. Int. J. Neuropsychopharmacol.6(1), 57–72 (2003).
   PubMed Web of Science ®Google Scholar
• Lévesque É , BeaulieuM, GuillemetteC, HumDW, BélangerA. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology139(5), 2375–2381 (1998).
   PubMed Web of Science ®Google Scholar
• Zhou T , ChenY, HuangC, ChenG. Caffeine induction of sulfotransferases in rat liver and intestine. J. Appl. Toxicol.32(10), 804–809 (2012).
   PubMed Web of Science ®Google Scholar
• Wang L-Q , JamesM. Inhibition of sulfotransferases by xenobiotics. Curr. Drug Metab.7(1), 83–104 (2006).
   PubMed Web of Science ®Google Scholar
• Allocati N , MasulliM, DiIlio C, FedericiL. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis7(1), 1–15 (2018).
   PubMedGoogle Scholar
• Vogel HG , HockFJ, MaasJ, MayerD. Safety and pharmacokinetic assays. In: Drug Discovery and Evaluation (2nd Edition). Springer Science & Business Media, Heidelberg, Germany (2006).
   Google Scholar
• Li Y , ZhouD, FergusonSS, DorffP, SimpsonTR, GrimmSW. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450 enzyme identification, inhibition, and induction studies. Xenobiotica40(11), 721–729 (2010).
   PubMed Web of Science ®Google Scholar
• US FDA . In Vitro Drug Interaction Studies–Cytochrome P450 Enzyme- and Drug Interactions Guidance for Industry In Vitro Drug Interaction Studies (2020). https://www.fda.gov/media/134582/download
   Google Scholar
• Hofstaedter F , EbnerR. The use of 3-D cultures for high-throughput screening. J. Biomol. Screen.9(4), 273–285 (2004).
   PubMedGoogle Scholar
• Bhatia SN , IngberDE. Microfluidics organ-on-chips: a perspective. Nat. Biotechnol.32, 760–772 (2014).
   PubMed Web of Science ®Google Scholar
• Esch EW , BahinskiA, HuhD. Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov.14(4), 248–260 (2015).
   PubMed Web of Science ®Google Scholar
• Deng J , ZhangX, ChenZet al. A cell lines derived microfluidic liver model for investigation of hepatotoxicity induced by drug–drug interaction. Biomicrofluidics13, 024101 (2019).
   PubMed Web of Science ®Google Scholar
• Tuschl G , HrachJ, WalterY, HewittPG, MuellerSO. Serum-free collagen sandwich cultures of adult rat hepatocytes maintain liver-like properties long term: a valuable model for in vitro toxicity and drug–drug interaction studies. Chem. Biol. Interact.181(1), 124–137 (2009).
   PubMed Web of Science ®Google Scholar
• Yamamoto N , WuJ, ZhangYet al. An optimal culture condition maintains human hepatocyte phenotype after long-term culture. J. Hepatol.35(3), 169–177 (2006).
   Google Scholar
• Das A , SligarSG. Modulation of the cytochrome P450 reductase redox potential by the phospholipid bilayer. Biochemistry48, 12104–12112 (2009).
   PubMed Web of Science ®Google Scholar
• Rowland A , GaganisP, ElliotDJ, MackenziePI, KnightsKM, MinersJO. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-Glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J. Pharmacol. Exp. Ther.321(1), 137–147 (2007).
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency (Japan) . Guideline on Drug Interaction for Drug Development and Appropriate Provision of Information (2019). https://www.xenotech.com/access-adme-research-resources/resources/2019-japanese-pmda-guideline-english-translation/
   Google Scholar
• Yoshida K , ZhaoP, ZhangLet al. In vitro–in vivo extrapolation of metabolism- and transporter-mediated drug–drug interactions—overview of basic prediction methods. J. Pharm. Sci.106(9), 2209–2213 (2017).
   PubMed Web of Science ®Google Scholar